BlueHalo's FE-1 Low-Cost Surface-To-Air Missile Fired For First Time
BlueHalo has, for the first time, launched its Freedom Eagle-1 (FE-1) missile, being developed for the U.S. Army's Next-Gen Counter-Uncrewed Aerial System (C-UAS) program. The new missile, intended to be relatively cheap to procure and able to be built rapidly in volume, is part of a new multi-pronged Army effort to better meet the proliferating drone threat head-on.
The successful live-fire demonstration of the FE-1 Controlled Test Vehicle (CTV) was only recently announced but took place from Jan. 16-18 this year, at Yuma Proving Ground, Arizona. It was conducted as part of the Next-Generation C-UAS Missile (NGCM) program, which aims to ramp up America's munitions industrial base to meet rapidly evolving aerial threats, specifically drones.
'In light of recent global events, including activities in Europe, the Red Sea, and Taiwan, we're taking a proactive stance — increasing internal investments to advance our FE-1 system and leaning in to meet the demand signal on an expedited timeline,' said Jonathan Moneymaker, BlueHalo chief executive officer.
The successful live fire demonstration of our Next-Gen #CUAS Missile, Freedom Eagle-1, shows how #TeamBlueHalo is addressing the critical need to meet rapidly evolving advanced aerial threats. We went from paper design to first flight in 107 days and we're thrilled to get one… pic.twitter.com/68QyfB27z1
— BlueHalo (@BlueHalo) March 13, 2025
The CTV live-fire demonstration at Yuma Proving Ground involved three missile test flights. 'In each of the three tests, FE-1 launched successfully and performed its flight as planned, affirming BlueHalo's commitment to a rapid development schedule. The team collected video, system, and sensor data logs, radar tracks, and RF diagnostics data from each flight test to evaluate the missile's guidance, navigation, and control systems and analyze aerodynamic models to drive down the significant technical risks associated with the program,' the company said.
The FE-1 launcher used for the Yuma tests was mounted on a flatbed trailer and was a simple cage-like construction, for a single missile, apparently intended only as a test rig. In the past, BlueHalo presented at least one concept for a four-round box-type launcher mounted on a pedestal atop a Stryker 8×8 wheeled armored fighting vehicle. This application, as well as a ship-based launcher (at around the 1:05 mark) are seen in the video below:
In keeping with its ambition of getting production-ready missiles into operational service sooner rather than later, the development of the FE-1 to date has been rapid.
In June of last year, BlueHalo announced that it had been selected as one of two vendors chosen to continue development of the NGCM by the U.S. Army Combat Capabilities Development Command Aviation & Missile Center (CCDC AvMC) Aviation & Missile Technology Consortium (AMTC).
Just two months later, the company announced the completion of multiple rounds of testing for the FE-1 low-cost effector, including the successful firing of its dual-thrust, solid-fuel rocket motor.
As of last December, BlueHalo had completed warhead detonation testing, which provided data on penetration depths, velocities, impacts, and panel fragmentation patterns.
Overall, it took BlueHalo 107 days to go from 'paper design to first flight,' the company says.
The next step is planned to include a customer live-fire demonstration in the third quarter of this year.
'It's clear that the new administration wants middle-tier acquisition going faster and fielding technology quicker,' explained Moneymaker. 'Additionally, Congress is supportive of additional effectors to get longer range, at higher altitudes, against a threat that is evolving faster than we can keep pace with current systems. We're moving at the speed necessary to meet the need, even if it requires our own internal funding to make it happen.'
The FE-1 is specifically designed to counter larger drones, in Group 3 and above. The U.S. military defines Group 3 drones as weighing between 55 and 1,320 pounds, being able to fly at altitudes between 3,500 and 18,000 feet, and having top speeds of between 100 and 250 knots.
To defeat threats such as these, the FE-1 is intended to have improved maneuverability, range, and rapid launch capabilities compared with current systems.
As well as drones, the FE-1 is intended to defeat various other 'larger air threats,' and to be integrated with existing infrastructure and command and control (C2) systems.
NGCM is one of at least four U.S. Army counter-drone-related competitions that are now underway, and which also include efforts to field a handheld C-UAS system for soldiers in combat, as well as a counter-drone radar.
As well as BlueHalo, Raytheon was selected as a vendor for NGCM development, for which it's preparing its Coyote.
Yet more contenders could still emerge, however.
'There are other companies out there that are working on interceptors for a counter-UAS application that might actually also have growth of potential to intercept … large caliber rockets, as well as potentially cruise missiles,' Brig. Gen. Frank Lozano, the Army's program executive officer for missiles and space, said in August of last year.
While Raytheon is well established in the field, BlueHalo is a relative upstart, but it is currently carving a niche as a specialist in innovative C-UAS solutions.
These also include directed-energy weapons, like the company's LOCUST laser weapon system — which you can read more about here. Meanwhile, the BlueHalo SkyView system provides for autonomous detection and precision tracking of small drones, using radio-frequency (RF) technology. Titan, another RF-based C-UAS solution from the same company, can detect, track, and force drones to safely land without disrupting nearby communications or electronics.
As we have discussed many times in the past, the threats posed by drones, including weaponized commercial types, are by no means new.
Nevertheless, the conflict in Ukraine has prompted a much wider rethink of C-UAS capabilities and how best to combat the various tiers of drones that might be operated by adversaries now and in the future. In particular, the requirement to be able to defend critical fixed infrastructure has been repeatedly demonstrated, most prominently by relentless Russian attacks on Ukraine using Shahed/Geran series long-range one-way attack drones. At the same time, there is a clear need to protect tanks and other armored vehicles against drones, especially highly maneuverable first-person view (FPV) kamikaze types.
A new air defense missile from a U.S. manufacturer is far from an everyday occurrence, making the emergence of the FE-1 notable in itself. At the same time, it is indicative of growing Army efforts to dramatically expand its air defense and counter-drone capabilities and capacity. Time will tell whether the Freedom Eagle-1 will also be a part of that future ecosystem.
Contact the author: thomas@thewarzone.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
20 minutes ago
- Newsweek
National Guard Gets First Ever 'Electromagnetic Warfare' Unit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A branch of the National Guard has established a new unit dedicated to electronic warfare (EW), the first of its kind in the U.S. Army. Why It Matters Wielding the electromagnetic spectrum to one side's advantage while jeopardizing how the enemy can communicate or use its weapons is a crucial part of fighting a war. Military forces can use the electromagnetic spectrum to pick up on and track targets, communicate between soldiers or units and coordinate strikes with accurate location data. EW interferes with these functions, making it harder for an adversary to carry out missions like accurate strikes guided by reliable navigation data. Captain Caleb D. Rogers, commander of the 111th Electromagnetic Warfare Company, receives the recently uncased unit guidon from Lt. Col. Luke E. Gurley, commander of the 221st Intelligence and Electronic Warfare Battalion, assuming his new... Captain Caleb D. Rogers, commander of the 111th Electromagnetic Warfare Company, receives the recently uncased unit guidon from Lt. Col. Luke E. Gurley, commander of the 221st Intelligence and Electronic Warfare Battalion, assuming his new role as commander, June 7, 2025 in Forest Park, Ga. More Charles Emmons/ National Guard Russia and Ukraine have both used EW extensively in the more than three years of full-scale war in eastern Europe. EW has also figured heavily into fighting in the Middle East, including on Israel's northern border with Lebanon. What To Know The 111th Electronic Warfare Company, part of the 221st Intelligence and Electronic Warfare Battalion, "made history" by becoming the "first unit of its kind in the U.S. Army," the Georgia Army National Guard said on Monday. The unit's creation "marks a significant step in modernizing the Army's capabilities within a domain that is increasingly critical to national security," the Georgia Army National Guard added in a statement. The U.S. Army chief of staff, General Randy George, has said the modern battlefield is constantly changing, and the U.S. military must follow suit. "We have been watching what's happening in the battlefield here with Ukraine, the Middle East, really, around the world," he said during an appearance at the Council on Foreign Relations think tank in May. "All of our soldiers are expected to keep up with evolving technology," said company commander, Captain Caleb Rogers, who heads the new EW unit. "It's a great time to be in military intelligence and electromagnetic warfare," added Brigadier General Theodore Scott III, the head of the 78th Troop Command and former chief of the 221st Intelligence and Electronic Warfare Battalion. The 221st Intelligence and Electronic Warfare Battalion has previously deployed to the Middle East and has supported the U.S.'s Indo-Pacific Command. What People Are Saying Lieutenant Colonel Luke Gurley, commander of the 221st Intelligence and Electronic Warfare Battalion which oversees the 111th Electromagnetic Warfare Company, said the unit "will be at the forefront of our capabilities in the electromagnetic spectrum." "All of our Soldiers are expected to keep up with evolving technology, and the unit as a whole is remaining flexible with the expectation of receiving a growing number of mission types," said company commander, Captain Caleb Rogers. What Happens Next The 111th will carry out its first field exercise in August at the Chattahoochee National Forest, the Georgia Army National Guard said. Drills will focus on picking up and identifying both static and moving targets as well as training to use electromagnetic technology.


Business Wire
3 hours ago
- Business Wire
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. AI-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world Share The results validate the power of IPA's LENSai™ platform and its proprietary HYFT™ technology, which enables first-principles-based in silico peptide discovery and optimization. Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates outperformed or matched Semaglutide under controlled assay conditions. Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach. 'This is not a one-off success,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENSai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1.' IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates: Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.


Business Upturn
3 hours ago
- Business Upturn
Breakthrough From NOVA Named 'Mushroom Powder Product of the Year' In 2025 Mindful Awards Program
LOS ANGELES, June 12, 2025 (GLOBE NEWSWIRE) — The 2025 Mindful Awards Program, an independent recognition platform highlighting conscious companies and products that mindfully make waves in the ever-expanding world of consumer-packaged goods, today announced that Breakthrough from NOVA , a trailblazer in the realm of women's holistic wellness, has been selected as 'Mushroom Powder Product of the Year' in the 7th annual awards program. Breakthrough from NOVA is a dynamic wellness drink mix for performance, energy, and focus. The functional mushroom powder-based formula is engineered to adapt to the unique demands of women and support the full spectrum of a woman's body, brain, and being. The NSF Certified for Sport® drink mix blends seven adaptogens, including a proprietary, clinically tested, full-spectrum mushroom compound made from six organic U.S.-grown species: cordyceps, lion's mane, reishi, turkey tail, shiitake, and king trumpet. Breakthrough is also beneficial for women navigating GLP-1 regimens as it helps to support gut diversity and microbiome health. Adaptogens like Rhodiola rosea (Rhodiolife®) and cordyceps also help to restore energy and endurance as well as preserve muscle. The formula's D-ribose promotes cellular recovery, and its CBD + biotech targets the ECS, reinforcing hormonal balance and emotional resilience. With lion's mane delivering superior gut-brain support, the gut is better prepared to intake nutrients. Breakthrough's mushrooms are full-spectrum and unextracted, preserving their naturally occurring beta-glucans and polyphenols to offer deeper gut and immune support. In addition, Rhodiolife® has also been clinically tested to help regulate cortisol, support mood and muscles during exercise and enhance recovery. NOVA's patented biotech (DehydraTECH™) delivers CBD with 10x absorption, while D-ribose, a naturally occurring sugar critical to ATP production, helps to fight fatigue and fuel cellular energy. The demand for consumer packaged goods (CPGs) remains largely consistent and constant even as consumer preferences evolve and change. The CPG market size is forecast to increase by USD 1,476.3 billion between 2024 and 2029. In 2025, sustainability is the CPG sector's newest consideration along with health-conscious consumer-driven trends and a shift toward e-commerce. With consumers relying more heavily on third-party validation when making new purchasing decisions, the Mindful Awards help brands and services stand out by showcasing products and services that represent the best in transparent, fair, natural, organic, sustainable, healthy, and delicious innovations. All nominations have been evaluated by an independent panel of experts within the consumer-packaged goods industry. 'Breakthrough isn't just a supplement—it's a science-backed power move for the modern, multidimensional woman, representing a revolutionary fusion of ancient wisdom and biotech-driven performance. Humans are unique and many single-ingredient solutions serve as one size fits all products that don't take into consideration that true wellness is the ability to adapt and empower individual bodies to thrive in every dimension,' said Travis Grant, Managing Director, Mindful Awards. 'Breakthrough's formula makes it a truly adaptive system that tunes itself to what each woman needs most. Mental clarity. Physical power. Recovery. Calm. Balance. Breakthrough meets women exactly where they are and supports them wherever they're going.' With scientifically proven benefits in performance, endurance, energy metabolism, stress resilience, and immune support, Breakthrough is designed to elevate physical, cognitive, and emotional wellness. Clinical trials show increased peak power, stamina, and endurance. 'At NOVA, we believe wellness shouldn't shrink a woman, it should fuel her expansion. Not every woman is the same, so our products, like Breakthrough, celebrate women as the complex, ever-evolving forces of nature they are. Breakthrough was formulated to be a revolution in a packet, challenging what wellness looks like and who it's actually for,' said Kathryn Robinson, Founder of NOVA. 'We're proud to accept the Mindful Award for 'Mushroom Powder Product of the Year!' We remain committed to quality and safety, and we'll continue to deliver multi-dimensional products that give our customers—whether athletes, professionals, moms, or all three—the confidence and results they need in a product they can trust.' The 2025 Mindful Awards winners range from groundbreaking food and beverage products to sustainable household solutions, redefining consumer experiences worldwide. This year's program attracted thousands of nominations from companies all over the world whose innovations enhance daily living, promote sustainability, and improve quality of life. About Mindful Awards The Mindful Awards organization is devoted to honoring mindful companies in the consumer-packaged goods industry that are setting the foundation for our future. Mindful Awards are devoted to providing a forum for public recognition around the achievements in categories Food, Beverage, Snacks, Supplements, Home, and Personal Care. Our mission is to bring awareness to the benefits of mindfulness and its impact on society as a whole. We believe that through mindfulness, we can create a more compassionate and sustainable world. For more information visit About NOVA NOVA emerges as a pioneering force in the realm of women's holistic wellness. As an innovative company, NOVA crafts more than just scientifically-backed products; it creates experiences that deeply resonate with the essence of womanhood for all women. NOVA is a genuine and authentic celebration of women in their entirety. Championing every element of a woman's journey, NOVA equips women with innovative wellness products and a community to design and realize their unique purpose. At the core of NOVA's ethos lies a commitment to excellence, innovation and challenging the status quo, placing the company at the forefront of the wellness revolution. NOVA's products are meticulously designed to cater to the multifaceted needs of diverse women, each blending empowerment, science, and integrity. Steadfast in breaking barriers, NOVA strives to redefine and create new standards that authentically represent women's experiences, endurance, achievements, and transformations because women are as diverse and multi-dimensional as the universe. Media Contact:Travis Grant Mindful Awards [email protected] 949.667.4475